NTAGI may soon review efficacy data of India's first intranasal Covid vaccine
Copyright:(C)2022 Bennett Coleman & Co. Ltd, http://info.indiatimes.com/terms/tou.html
economics
2022-06-01 18:54:17

AgenciesBharat Biotech has developed the single-dose, intranasal vaccine in partnership with Washington University in St Louis, US. The National Technical Advisory Group on Immunisation (NTAGI) is likely to review safety and efficacy data of India's first intranasal Covid-19 vaccine by Hyderabad-based Bharat Biotech at a meeting slated for this month. "The company has approached us to give a presentation on its intranasal vaccine. We will invite them to our meeting," people in the know told ET. The date of the meeting is yet to be fixed.
